SuperworthHeartSciences revenue HSCS
Sales by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jul 31, 2026
- $4.5K
- Latest quarter, Q1 FY27
- $2.1K
- +11% on a year earlier
- Fiscal year 2026
- $4.3K
HeartSciences' revenue was $4.5K over the twelve months to Jul 31, 2026.
In its latest quarter, Q1 FY27, it was $2.1K, up 11% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2026 | $4.3K | n/a |
| FY2025 | n/a | n/a |
| FY2024 | n/a | n/a |
| FY2023 | $5.2K | −64% |
| FY2022 | $14.4K | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | $2.1K | +11% | $4.5K | |
| Q4 FY26 | $0 | −100% | $4.3K | |
| Q3 FY26 | $0 | n/a | $8.7K | |
| Q2 FY26 | $2.4K | n/a | $8.7K | |
| Q1 FY26 | $1.9K | n/a | n/a | |
| Q4 FY25 | $4.3K | n/a | n/a | |
| Q3 FY25 | $0 | −100% | n/a | |
| Q4 FY24 | $0 | n/a | n/a | |
| Q3 FY24 | $14.7K | +654% | n/a | |
| Q2 FY24 | $3.9K | n/a | n/a | |
| Q4 FY23 | $0 | −100% | $5.2K | |
| Q3 FY23 | $1.9K | −29% | $9.3K |
Against its peers
Companies in Financial - Credit Services nearest HeartSciences' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| HSCSHeartSciences | $4.5K | |
| BCGBinah Capital | $191.9M | +8% a year |
| VIPVulcan Infrastructure & Power | $50.9M | −14% a year |
| ATCHAtlasClear | $20.1M | +85% a year |
| RSSSResearch Solutions | $48.3M | −2% a year |
| MACIMelar Acquisition Corp. I/Cayman | n/m | |
| Peer median | $49.6M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on HeartSciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.